Monday, October 10, 2016

Helidac


Helidac is a brand name of bismuth subsalicylate/metronidazole/tetracycline, approved by the FDA in the following formulation(s):


HELIDAC (bismuth subsalicylate; metronidazole; tetracycline hydrochloride - tablet, chewable, tablet, capsule; oral)



  • Manufacturer: PROMETHEUS LABS

    Approval date: August 15, 1996

    Strength(s): 262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG [RLD]

Has a generic version of Helidac been approved?


No. There is currently no therapeutically equivalent version of Helidac available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Helidac. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Helidac.

See also...

  • Helidac Therapy Pack Consumer Information (Wolters Kluwer)
  • Helidac Consumer Information (Cerner Multum)
  • Helidac Advanced Consumer Information (Micromedex)
  • Bismuth Subsalicylate/Metronidazole/Tetracycline Therapy Pack Consumer Information (Wolters Kluwer)
  • Bismuth subsalicylate, metronidazole, and tetracycline Consumer Information (Cerner Multum)
  • Bismuth subsalicylate, metronidazole, and tetracycline Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:

DynaCirc CR


DynaCirc CR is a brand name of isradipine, approved by the FDA in the following formulation(s):


DYNACIRC CR (isradipine - tablet, extended release; oral)



  • Manufacturer: GLAXOSMITHKLINE LLC

    Approval date: June 1, 1994

    Strength(s): 10MG [RLD], 5MG

Has a generic version of DynaCirc CR been approved?


No. There is currently no therapeutically equivalent version of DynaCirc CR available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of DynaCirc CR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with DynaCirc CR.

See also...

  • DynaCirc CR Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Dynacirc CR Consumer Information (Cerner Multum)
  • Dynacirc CR Advanced Consumer Information (Micromedex)
  • Isradipine Consumer Information (Wolters Kluwer)
  • Isradipine Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Isradipine Consumer Information (Cerner Multum)
  • Isradipine Advanced Consumer Information (Micromedex)
  • Isradipine AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Anturol


Anturol is a brand name of oxybutynin, approved by the FDA in the following formulation(s):


ANTUROL (oxybutynin - gel, metered; transdermal)



  • Manufacturer: ANTARES PHARMA INC

    Approval date: December 7, 2011

    Strength(s): 3% [RLD]

Has a generic version of Anturol been approved?


No. There is currently no therapeutically equivalent version of Anturol available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Anturol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Anturol.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • December 7, 2014 - NEW PRODUCT

See also...

  • Anturol Consumer Information (Drugs.com)
  • Anturol Advanced Consumer Information (Micromedex)
  • Oxybutynin Consumer Information (Drugs.com)
  • Oxybutynin Consumer Information (Wolters Kluwer)
  • Oxybutynin Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Oxybutynin Gel Consumer Information (Wolters Kluwer)
  • Oxybutynin Syrup Consumer Information (Wolters Kluwer)
  • Oxybutynin System Consumer Information (Wolters Kluwer)
  • Oxybutynin Consumer Information (Cerner Multum)
  • Oxybutynin topical Consumer Information (Cerner Multum)
  • Oxybutynin transdermal Consumer Information (Cerner Multum)
  • Oxybutynin Advanced Consumer Information (Micromedex)
  • Oxybutynin Transdermal Advanced Consumer Information (Micromedex)
  • Oxybutynin Chloride AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Capoten


Capoten is a brand name of captopril, approved by the FDA in the following formulation(s):


CAPOTEN (captopril - tablet; oral)



  • Manufacturer: PAR PHARM

    Approved Prior to Jan 1, 1982

    Strength(s): 100MG [RLD][AB], 25MG [AB], 50MG [AB]


  • Manufacturer: PAR PHARM

    Approval date: January 17, 1985

    Strength(s): 12.5MG [AB]

Has a generic version of Capoten been approved?


Yes. The following products are equivalent to Capoten:


captopril tablet; oral



  • Manufacturer: APOTEX

    Approval date: October 28, 1998

    Strength(s): 100MG [AB], 12.5MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: MYLAN

    Approval date: February 13, 1996

    Strength(s): 100MG [AB], 12.5MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: PRINSTON INC

    Approval date: February 13, 1996

    Strength(s): 100MG [AB], 12.5MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: SANDOZ

    Approval date: November 9, 1995

    Strength(s): 100MG [AB], 12.5MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: STASON

    Approval date: May 30, 1997

    Strength(s): 100MG [AB], 12.5MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: TEVA

    Approval date: February 13, 1996

    Strength(s): 100MG [AB], 100MG [AB], 12.5MG [AB], 12.5MG [AB], 25MG [AB], 25MG [AB], 50MG [AB], 50MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: February 13, 1996

    Strength(s): 100MG [AB], 12.5MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: May 23, 1996

    Strength(s): 100MG [AB], 12.5MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: WEST WARD

    Approval date: February 13, 1996

    Strength(s): 100MG [AB], 12.5MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: WOCKHARDT

    Approval date: March 28, 1997

    Strength(s): 100MG [AB], 12.5MG [AB], 25MG [AB], 50MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Capoten. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Capoten.

See also...

  • Capoten Consumer Information (Drugs.com)
  • Capoten Consumer Information (Wolters Kluwer)
  • Capoten Consumer Information (Cerner Multum)
  • Capoten Advanced Consumer Information (Micromedex)
  • Capoten AHFS DI Monographs (ASHP)
  • Captopril Consumer Information (Drugs.com)
  • Captopril Consumer Information (Wolters Kluwer)
  • Captopril Consumer Information (Cerner Multum)
  • Captopril Advanced Consumer Information (Micromedex)
  • Captopril AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Tazorac


Tazorac is a brand name of tazarotene topical, approved by the FDA in the following formulation(s):


TAZORAC (tazarotene - cream; topical)



  • Manufacturer: ALLERGAN

    Approval date: September 29, 2000

    Strength(s): 0.05% [RLD], 0.1% [RLD]

TAZORAC (tazarotene - gel; topical)



  • Manufacturer: ALLERGAN

    Approval date: June 13, 1997

    Strength(s): 0.05% [RLD], 0.1% [RLD]

Has a generic version of Tazorac been approved?


No. There is currently no therapeutically equivalent version of Tazorac available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tazorac. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Stable gel formulation for topical treatment of skin conditions
    Patent 5,914,334
    Issued: June 22, 1999
    Inventor(s): Charu; Prakash M.
    Assignee(s): Allergan, Inc.
    The present invention provides a stable gel formulation for topical treatment of skin conditions in humans. The stable gel formulation includes an active agent, having activity for treatment of acne and psoriasis, which is insoluble in water and a plurality of nonaqueous vehicles for both solubilizing said active agent and forming a gel therewith enabling topical application of the gel to a skin condition. The plurality of vehicles are each present in amounts, and in combination, to control release of the active agent from the gel to the skin condition.
    Patent expiration dates:

    • June 7, 2014
      ✓ 
      Patent use: STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS




  • Stable gel formulation for topical treatment of skin conditions
    Patent 6,258,830
    Issued: July 10, 2001
    Inventor(s): Charu; Prakash M.
    Assignee(s): Allergan Sales, Inc.
    The present invention provides a stable gel formulation for topical treatment of skin conditions in humans. The stable gel formulation includes an active agent, having activity for treatment of acne and psoriasis, which is insoluble in water and a plurality of nonaqueous vehicles for both solubilizing said active agent and forming a gel therewith enabling topical application of the gel to a skin condition. The plurality of vehicles are each present in amounts, and in combination, to control release of the active agent from-the gel to the skin condition.
    Patent expiration dates:

    • June 7, 2014
      ✓ 
      Patent use: STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS



See also...

  • Tazorac Cream Consumer Information (Wolters Kluwer)
  • Tazorac Gel Consumer Information (Wolters Kluwer)
  • Tazorac Consumer Information (Cerner Multum)
  • Tazorac Topical Advanced Consumer Information (Micromedex)
  • Tazarotene Cream Consumer Information (Wolters Kluwer)
  • Tazarotene Gel Consumer Information (Wolters Kluwer)
  • Tazarotene topical Consumer Information (Cerner Multum)
  • Tazarotene Topical Advanced Consumer Information (Micromedex)
  • Tazarotene AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Agrylin


Agrylin is a brand name of anagrelide, approved by the FDA in the following formulation(s):


AGRYLIN (anagrelide hydrochloride - capsule; oral)



  • Manufacturer: SHIRE LLC

    Approval date: March 14, 1997

    Strength(s): EQ 0.5MG BASE [AB]

Has a generic version of Agrylin been approved?


Yes. The following products are equivalent to Agrylin:


anagrelide hydrochloride capsule; oral



  • Manufacturer: ALPHAPHARM

    Approval date: June 27, 2006

    Strength(s): EQ 0.5MG BASE [AB]


  • Manufacturer: BARR

    Approval date: April 18, 2005

    Strength(s): EQ 0.5MG BASE [AB]


  • Manufacturer: IMPAX LABS

    Approval date: April 18, 2005

    Strength(s): EQ 0.5MG BASE [AB]


  • Manufacturer: IVAX SUB TEVA PHARMS

    Approval date: April 18, 2005

    Strength(s): EQ 0.5MG BASE [AB]


  • Manufacturer: MYLAN

    Approval date: April 18, 2005

    Strength(s): EQ 0.5MG BASE [AB]


  • Manufacturer: SANDOZ

    Approval date: April 18, 2005

    Strength(s): EQ 0.5MG BASE [AB]


  • Manufacturer: WATSON LABS

    Approval date: April 18, 2005

    Strength(s): EQ 0.5MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Agrylin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Agrylin.

See also...

  • Agrylin Consumer Information (Wolters Kluwer)
  • Agrylin Consumer Information (Cerner Multum)
  • Agrylin Advanced Consumer Information (Micromedex)
  • Agrylin AHFS DI Monographs (ASHP)
  • Anagrelide Consumer Information (Wolters Kluwer)
  • Anagrelide Consumer Information (Cerner Multum)
  • Anagrelide Advanced Consumer Information (Micromedex)
  • Anagrelide hydrochloride AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

ActoPlus Met


See also: Generic ActoPlus Met XR


ActoPlus Met is a brand name of metformin/pioglitazone, approved by the FDA in the following formulation(s):


ACTOPLUS MET (metformin hydrochloride; pioglitazone hydrochloride - tablet; oral)



  • Manufacturer: TAKEDA GLOBAL

    Approval date: August 29, 2005

    Strength(s): 500MG;EQ 15MG BASE [AB], 850MG;EQ 15MG BASE [RLD][AB]

Has a generic version of ActoPlus Met been approved?


A generic version of ActoPlus Met has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to ActoPlus Met and have been approved by the FDA:


PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE (metformin hydrochloride; pioglitazone hydrochloride tablet; oral)



  • Manufacturer: MYLAN

    Approval date: February 25, 2011

    Strength(s): 500MG;EQ 15MG BASE [AB], 850MG;EQ 15MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of ActoPlus Met. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Pharmaceutical composition
    Patent 5,965,584
    Issued: October 12, 1999
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE
      ✓ 
      Drug product




  • Pharmaceutical composition
    Patent 6,166,042
    Issued: December 26, 2000
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN




  • Pharmaceutical composition
    Patent 6,166,043
    Issued: December 26, 2000
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN




  • Pharmaceutical composition
    Patent 6,172,090
    Issued: January 9, 2001
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN



See also...

  • Actoplus Met Consumer Information (Drugs.com)
  • Actoplus Met Consumer Information (Wolters Kluwer)
  • Actoplus Met Consumer Information (Cerner Multum)
  • Actoplus Met Advanced Consumer Information (Micromedex)
  • Metformin Extended-Release/Pioglitazone Consumer Information (Wolters Kluwer)
  • Metformin/Pioglitazone Consumer Information (Wolters Kluwer)
  • Pioglitazone/Metformin Consumer Information (Wolters Kluwer)
  • Pioglitazone/Metformin Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Metformin and pioglitazone Consumer Information (Cerner Multum)
  • Metformin and pioglitazone Advanced Consumer Information (Micromedex)
  • Pioglitazone and metformin Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)